[Treatment of cerebrovascular insufficiency. A trial of orphol in 8940 patients by 800 medical practitioners (author's transl)].
A total of 800 physicians practising general medicine, internal medicine and neurology tested the dihydroergotoxin preparation Orphol Drops for a period of six weeks at a daily dose of 30 drops 3 times daily in 8940 patients with cerebrovascular insufficiency. The "cerebral symptom" complex showed the best results with improved findings in 94.5% of cases. The overall assessment of therapy by the doctors in the "psychological findings" complex showed improved findings in 85.7% of the patients affected after 6 weeks' treatment. The third complex, "harmonization of environmental relations" still showed improved findings in 71.6% of the affected patients. The sustained improvements in all three "complexes" were striking, also in the second period of the trial, which emphasizes the importance of longterm therapy of deficiency symptoms in cerebrovascular insufficiency.
D000368:Aged; D001008:Anxiety Disorders / Q000188:drug therapy; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D003072:Cognition Disorders / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D006261:Headache / Q000188:drug therapy; D006801:Humans; D000860:Hypoxia / Q000517:prevention & control; D008568:Memory / Q000187:drug effects; D014717:Vertigo / Q000188:drug therapy
D004088:Dihydroergotoxine
Therapie der zerebrovaskulären Insuffizienz. 800 niedergelassene Arzte prüften Orphol an 8940 Patienten.